The CPNE6 antibody targets Copine VI (CPNE6), a member of the copine protein family characterized by calcium-dependent phospholipid-binding domains. CPNE6 is predominantly expressed in the brain, particularly in the hippocampus and cerebral cortex, and is implicated in synaptic plasticity, neurotransmitter release, and neuronal signaling. Its calcium-sensitive structure allows it to bridge intracellular membranes with cytosolic signaling proteins, influencing pathways critical for learning and memory. Dysregulation of CPNE6 has been linked to neuropsychiatric and neurodegenerative disorders, including Alzheimer’s disease, though its precise mechanisms remain under investigation.
CPNE6 antibodies are essential tools for detecting and quantifying CPNE6 expression in research. They enable techniques like Western blotting, immunohistochemistry, and immunofluorescence to study its localization, expression levels, and interactions in neural tissues. These antibodies help explore CPNE6's role in synaptic function, such as modulating membrane trafficking or regulating calcium-dependent signaling cascades. Additionally, they aid in assessing CPNE6's potential as a biomarker or therapeutic target in neurological diseases.
Despite their utility, challenges persist, including ensuring antibody specificity due to homology within the copine family. Ongoing research aims to clarify CPNE6's multifaceted roles in health and disease, supported by advanced antibody-based methodologies.